Entero Therapeutics (FRA:366) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 23, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Entero Therapeutics (FRA:366) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Entero Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (FRA:366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines